Stryker’s (SYK) “Hold” Rating Reiterated at Truist Financial

Stryker (NYSE:SYK)‘s stock had its “hold” rating restated by research analysts at Truist Financial in a report released on Monday,Benzinga reports. They presently have a $392.00 price objective on the medical technology company’s stock, down from their prior price objective of $407.00. Truist Financial’s price target would suggest a potential upside of 9.78% from the company’s current price.

Other equities analysts also recently issued research reports about the stock. Rothschild & Co Redburn assumed coverage on shares of Stryker in a report on Thursday, September 18th. They set a “neutral” rating and a $420.00 price target for the company. Evercore ISI reduced their price target on shares of Stryker from $410.00 to $405.00 and set an “outperform” rating for the company in a report on Friday. Needham & Company LLC boosted their price target on shares of Stryker from $442.00 to $448.00 and gave the company a “buy” rating in a report on Friday, August 1st. Weiss Ratings reissued a “buy (b-)” rating on shares of Stryker in a report on Wednesday, October 8th. Finally, BTIG Research boosted their price target on shares of Stryker from $408.00 to $410.00 and gave the company a “buy” rating in a report on Friday. Fourteen research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $433.37.

Stryker Stock Up 0.2%

Shares of NYSE:SYK traded up $0.85 during midday trading on Monday, reaching $357.09. The company had a trading volume of 300,446 shares, compared to its average volume of 1,409,873. The stock has a market capitalization of $136.52 billion, a P/E ratio of 47.35, a PEG ratio of 2.66 and a beta of 0.94. The stock’s fifty day moving average price is $378.08 and its 200-day moving average price is $381.04. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. Stryker has a one year low of $329.16 and a one year high of $406.19.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 EPS for the quarter, topping analysts’ consensus estimates of $3.13 by $0.06. The firm had revenue of $6.06 billion during the quarter, compared to the consensus estimate of $6.04 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The firm’s revenue was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.87 earnings per share. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Equities research analysts expect that Stryker will post 13.47 earnings per share for the current fiscal year.

Insider Activity

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the business’s stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the sale, the director owned 3,222,108 shares in the company, valued at approximately $1,212,962,556.60. The trade was a 5.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Viju Menon sold 500 shares of the business’s stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the sale, the insider owned 12,511 shares in the company, valued at approximately $4,886,921.71. The trade was a 3.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 5.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Stryker

A number of institutional investors have recently modified their holdings of the stock. Mar Vista Investment Partners LLC boosted its position in shares of Stryker by 10.2% in the first quarter. Mar Vista Investment Partners LLC now owns 90,187 shares of the medical technology company’s stock valued at $33,572,000 after acquiring an additional 8,353 shares during the period. United Services Automobile Association acquired a new stake in Stryker during the first quarter worth $2,857,000. AXS Investments LLC boosted its stake in Stryker by 13.7% during the first quarter. AXS Investments LLC now owns 8,827 shares of the medical technology company’s stock worth $3,286,000 after buying an additional 1,062 shares in the last quarter. Park Edge Advisors LLC acquired a new stake in Stryker during the second quarter worth $679,000. Finally, Motco boosted its stake in Stryker by 3,157.8% during the second quarter. Motco now owns 23,228 shares of the medical technology company’s stock worth $9,122,000 after buying an additional 22,515 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.